A detailed history of Price T Rowe Associates Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,337,020 shares of MGNX stock, worth $4.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,337,020
Previous 2,438,050 45.16%
Holding current value
$4.27 Million
Previous $35.9 Million 84.16%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.31 - $18.51 $3.64 Million - $20.4 Million
-1,101,030 Reduced 45.16%
1,337,020 $5.68 Million
Q1 2024

May 15, 2024

BUY
$9.77 - $21.47 $23.5 Million - $51.7 Million
2,409,237 Added 8361.63%
2,438,050 $35.9 Million
Q4 2023

Feb 14, 2024

SELL
$4.48 - $10.11 $18,807 - $42,441
-4,198 Reduced 12.72%
28,813 $278,000
Q3 2023

Nov 14, 2023

BUY
$4.48 - $6.19 $35,992 - $49,730
8,034 Added 32.17%
33,011 $154,000
Q2 2023

Aug 14, 2023

BUY
$4.62 - $7.54 $1,081 - $1,764
234 Added 0.95%
24,977 $134,000
Q1 2023

May 15, 2023

BUY
$4.82 - $7.24 $4,704 - $7,066
976 Added 4.11%
24,743 $178,000
Q4 2022

Feb 14, 2023

BUY
$3.34 - $6.98 $18,744 - $39,171
5,612 Added 30.91%
23,767 $159,000
Q3 2022

Nov 14, 2022

SELL
$3.01 - $5.22 $20,567 - $35,668
-6,833 Reduced 27.35%
18,155 $63,000
Q2 2022

Aug 15, 2022

BUY
$2.25 - $9.99 $675 - $2,997
300 Added 1.22%
24,988 $74,000
Q1 2022

May 16, 2022

BUY
$8.12 - $16.9 $11,538 - $24,014
1,421 Added 6.11%
24,688 $218,000
Q4 2021

Feb 14, 2022

SELL
$15.91 - $21.88 $225,922 - $310,696
-14,200 Reduced 37.9%
23,267 $373,000
Q3 2021

Nov 15, 2021

BUY
$19.74 - $28.7 $86,856 - $126,280
4,400 Added 13.31%
37,467 $785,000
Q2 2021

Aug 16, 2021

SELL
$20.49 - $35.63 $450 - $783
-22 Reduced 0.07%
33,067 $888,000
Q1 2021

May 17, 2021

BUY
$18.99 - $33.2 $69,826 - $122,076
3,677 Added 12.5%
33,089 $1.05 Million
Q4 2020

Feb 16, 2021

BUY
$19.41 - $26.0 $570,886 - $764,712
29,412 New
29,412 $672,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $196M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.